Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Athersys Shares Jump After MultiStem Cell Therapy Data Published In Medical Journal
Athersys Inc (NASDAQ: ATHX) announced that a manuscript reporting data from its MUST-ARDS clinical trial
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 30)
Athersys: Q2 Earnings Insights
Shares of Athersys (NASDAQ:ATHX) increased in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were unchanged 0.00% over the past year to ($0.10), which were in line with the estimate of ($0.10).
Athersys Q2 EPS $(0.10), Inline
Athersys (NASDAQ:ATHX) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.